Literature DB >> 22514442

In search of the amazing technicolour dream coat for amphotericin B.

J Conly1, S Shafran.   

Abstract

Entities:  

Year:  1996        PMID： 22514442      PMCID： PMC3327406          DOI： 10.1155/1996/802587

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN： 1180-2332


× No keyword cloud information.
  26 in total

Review 1.  Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides.

Authors:  J A Karlowsky; G G Zhanel
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

2.  Amphotericin B does not mix with fat emulsion.

Authors:  L A Trissel
Journal:  Am J Health Syst Pharm       Date:  1995-07-01       Impact factor: 2.637

Review 3.  Current role of therapy with amphotericin B.

Authors:  R D Meyer
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

4.  Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.

Authors:  R M Fielding; A W Singer; L H Wang; S Babbar; L S Guo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.

Authors:  R J Coker; M Viviani; B G Gazzard; B Du Pont; H D Pohle; S M Murphy; J Atouguia; J L Champalimaud; J R Harris
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

6.  An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.

Authors:  R Kirsh; R Goldstein; J Tarloff; D Parris; J Hook; N Hanna; P Bugelski; G Poste
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

Review 7.  Clinical use of liposomal and lipid-complexed amphotericin B.

Authors:  S de Marie; R Janknegt; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

8.  Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.

Authors:  O Ringdén; F Meunier; J Tollemar; P Ricci; S Tura; E Kuse; M A Viviani; N C Gorin; J Klastersky; P Fenaux
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

9.  Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)--a report on 40 cases from a single centre.

Authors:  R Chopra; A Fielding; A H Goldstone
Journal:  Leuk Lymphoma       Date:  1992

Review 10.  Emergence of a new opportunistic pathogen, Candida lusitaniae.

Authors:  R J Blinkhorn; D Adelstein; P J Spagnuolo
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.